Regulatory approval

Published by the Health Service Executive. Approved

Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL).

This is written in the approval document.

Reimbursement

Incomplete Reimbursement

Brentuximab - ODMS; Bendamustine - N/A

Citation

Brentuximab vedotin and Bendamustine Therapy, 2024, version number 2, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6526/529_v2_Brentuximab_bendamustine.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	CD30 +	Hodgkin Lymphoma	Bendamustine, Brentuximab vedotin

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2021-10-18	Health Service Executive	Indication approved for reimbursement.